Home

GERALD T PROEHL

CIK 1279191 · PRESIDENT, CHAIRMAN, CEO · last filed 2026-08-18

GERALD T PROEHL is a PRESIDENT, CHAIRMAN, CEO who has filed 57 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for DRMA, was dated Aug 18, 2026. Across all open-market trades the lifetime net is −$10.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $442.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$442.7K

Companies

8

Total Filings

57

Lifetime Open-Market Net

-$10.78M

Filer Profile

Reported Address
10590 W OCEAN AIR DR
STE 200
SAN DIEGO, CA 92130
Phone
(858) 314-5700
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DRMA PRESIDENT, CHAIRMAN, CEO 31 $1.19 $37 $0 1 2026-08-18
TENX Director 1,667 $1.86 $3.1K $50.0K 8 2026-01-13
DRMAW President, CEO and Chairman 31 $0.00 $0 $97.6K 8 2026-01-06
THC Director 1,667 $263.69 $439.6K $0 1 2024-08-08
SOPHIRIS BIO INC. (SPHS) Delisted Director 10,000 — — $31.6K 7 2019-06-28
Qualigen Therapeutics, Inc. (RTTR) Delisted Director 200 — — $250.0K 4 2018-01-25
Auspex Pharmaceuticals, Inc. (ASPX) Delisted Director 0 — — $31.9K 2 2015-05-06
SANTARUS INC (SNTS) Delisted President & CEO 416,463 — — -$11.24M 25 2013-12-17

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-18 DRMA Grant (A) +170,068 $0 EDGAR
2026-01-13 TENX Grant (A) — $0 EDGAR
2026-01-06 DRMAW Grant (A) — $0 EDGAR
2025-12-29 DRMAW Mixed +612,745 $0 EDGAR
2025-07-03 TENX Grant (A) — $0 EDGAR
2025-01-23 DRMAW Grant (A) +787,402 $0 EDGAR
2025-01-14 DRMAW Grant (A) — $0 EDGAR
2024-12-12 TENX Grant (A) — $0 EDGAR
2024-08-08 THC Buy (P) +1,666 $0 EDGAR
2024-01-05 DRMAW Grant (A) — $0 EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.